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ostasis is observed in patients with hypothalamic lesions leading to hypothalamic obesity
(HO).This drastic condition is frequently seen in patients with craniopharyngioma (CP), an
embryological tumor located in the hypothalamic and/or pituitary region, frequently causing
not only hypopituitarism, but also leading to damage of medial hypothalamic nuclei due
to the tumor and its treatment. HO syndrome in CP patients is characterized by fatigue,
decreased physical activity, uncontrolled appetite, and morbid obesity, and is associated
with insulin and leptin resistance. Mechanisms leading to the profoundly disturbed energy
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HYPOTHALAMIC OBESITY IN PATIENTS WITH
CRANIOPHARYNGIOMA: SUMMARY OF KEY CLINICAL
FINDINGS
Excessive weight gain is one of the most distressing manifesta-
tions of hypothalamic injury associated with CP. In 30% of all
patients with hypothalamic tumors, BMI is increased at the time
of diagnosis (Muller et al., 2004). After surgery, hyperphagia and
obesity occur on average in about 50% of all CP patients (Cur-
tis et al., 1994; Muller et al., 2001; Muller, 2006), although study
results vary from 6% (Galatzer et al., 1981) to 91% (Imura et al.,
1987; Muller et al.,2004),with higher rates in patients with hypo-
thalamic damage. In children and adolescents, the incidence of
severe obesity following CP resection surgery is between 22 and
62% (Brauner et al., 1987; Sorva, 1988; Muller, 2008). Struc-
tural defects in parts of the medial hypothalamus due to surgery,
irradiation, or the tumor itself often cause treatment resistant
uncontrolled appetite and rapid weight gain. Tumor resection
with and without radiotherapy represents the therapeutic stan-
dard of care. But following treatment, patients often suffer from
partial hypopituitarism or panhypopituitarism. Despite optimal
endocrine management, uncontrolled appetite and rapid weight
gain are common, typically most pronounced during the ﬁrst
months after surgery (Sorva, 1988; Muller et al., 2004), making
severe obesity a major risk factor for CP related morbidity. Risk
factors for developing obesity in CP patients include large hypo-
thalamiclesionsaffectingseveralmedialhypothalamicnucleisuch
as the arcuate nucleus (ARC), ventromedial nucleus (VMN), and
the dorsomedial nucleus (DMN),and tumors that reach the ﬂoor
of the third ventricle; hydrocephalus; transcranial surgery, which
often causes greater damage to the hypothalamus compared to
transnasal surgical tumor removal; aggressiveness of resection;
reoperation for tumor recurrence; and hypothalamic irradiation
(Mulleretal.,2007;Gardneretal.,2008;Vinchonetal.,2009;Roth
et al.,2011c; Figure 1).
KEY BRAIN AREAS AND NEURONAL PATHWAYS INVOLVED
IN ENERGY HOMEOSTASIS
HYPOTHALAMIC NUCLEI AND WEIGHT REGULATORY PATHWAYS
The hypothalamus is central to regulation of energy homeosta-
sis. Hypothalamic nuclei are the target of circulating peptides,
including leptin, insulin, peptide YY3–36 (PYY), and ghrelin, as
well as nutrients such as free fatty acids, glucose, and amino acids
(Schwartz et al., 2000; Cota et al., 2006; Morton et al., 2006; Par-
ton et al., 2007). Changes in the circulating level of these afferent
inputs can trigger potent efferent responses affecting both food
intake(FI)andenergyexpenditure(EE)intheregulationofenergy
homeostasis. It is well established that insulin and leptin are two
peripherally secreted hormones that play critical roles in FI and
EE(Schwartzetal.,2000)andthatlevelsof bothareproportionate
to body fat and interact with their respective receptors expressed
in the ARC, a key brain area transmitting peripheral weight-
regulating signals to the brain. Many neurons are regulated by
leptin and insulin, and central administration of either hormone
reduces FI and body weight. The main mediators in the hypothal-
amic regulation of energy intake and EE appear to be proopiome-
lanocortin (POMC) and neuropeptide-Y/agouti-related peptide
(NPY/AgRP) producing neurons, which are concentrated in the
ARC and project mainly to the paraventricular nucleus (PVN)
in the hypothalamus but also to the VMN, lateral hypothalamus
(LHA),aswellastheDMNandthemedianpreopticarea(Baietal.,
1985;KerkerianandPelletier,1986;Schwartzetal.,2000;Schwartz
and Gelling, 2002). Alpha-melanocyte stimulating hormone (α-
MSH), a posttranslational product of the prohormone POMC, is
one of the key weight-regulating neuropeptides (Bai et al., 1985;
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FIGURE 1 | Representative coronal (A), midsagittal brain MRI (B), and
schematic overview (C,D) of a patient with hypothalamic obesity and
hyperphagia following surgery for CP . Lesion affects the ARC, VMN,
DMN, and the posterior part of the AHA, but not the LHA. DMN,
dorsomedial nucleus; LHA, lateral hypothalamus; VMN, ventromedial
nucleus; PVN, paraventricular nucleus; ARC, arcuate nucleus; AHA, anterior
hypothalamic area.
Kerkerian and Pelletier, 1986; Schwartz et al., 2000; Schwartz and
Gelling, 2002). The VMN contains gamma-amino butyric acid-
(GABA)ergic and anorexigenic brain-derived neurotrophic factor
(BDNF) neurons and is an important nucleus for insulin depen-
dentneurotransmissionandisanimportantsitefortheregulation
of the autonomous nervous system outﬂow from the brain (Mor-
tonetal.,2006;BerthoudandMorrison,2008).TheDMNcontains
GABAergic neurons but also expresses NPY in particular in its
compact region and expresses leptin receptors such as the ARC,
VMN, and PVN (Choi et al., 1999; Glavas et al., 2007). NPY in
the DMN may play a role in maintaining energy homeostasis (Bi,
2007). The PVN receives projections from NPY-synthesizing neu-
rons located in the ARC, which are also present in the brainstem
(Sawchenko et al., 1985; Sahu et al., 1988). Neurons that synthe-
size the hunger hormones, MCH or orexin A, are located in the
LHAandaredownstreammediatorsof feedingresponsesinitiated
by ARC neurons (Schwartz, 2006). The PVN contains a variety
of appetite suppressing peptides, such as corticotropin-releasing
factor (CRF), thyrotropin-releasing hormone (TRH), and oxy-
tocin, that promote negative energy balance by conveying input
from theARC to other key brain areas such as the NTS (Schwartz,
2006; Blevins et al., 2009). Recent evidence also suggests that the
adiposity hormones act in brain areas linked with food reward,
whichmediatemotivationandthedecisiontoeat.(Petrovichetal.,
2002;FiglewiczandBenoit,2009).Limbicandrewardcircuitryare
densely innervated by neurocircuits originating in the hypothal-
amus and are directly responsive to ghrelin, leptin, and insulin
(Figlewicz, 2003; Figlewicz et al., 2007). These structures receive
signiﬁcantcorticalinputaswell,sendingprojectionstothenucleus
accumbens and pallidum, and from there, via the LHA, to motor
regions charged with executing feeding behavior.
HINDBRAIN SIGNALING AND PERIPHERAL REGULATORS




igenic hormones inhibit FI through neurons in the ARC, which
is frequently damaged in CP patients, and/or neurons located in
the hindbrain solitary tract nucleus, which is usually intact in CP
patients (Batterham et al., 2002; Small et al., 2005). Addition-
ally, plasma concentrations of orexigenic ghrelin decrease after
FI. An intact vagal-brainstem-hypothalamic pathway is required
in order for some of these hormones to exert their effects on FI
which is controversial for PYY (Batterhametal.,2002;Smalletal.,
2005).Althoughthereispublishedevidencethatincreasedinsulin
secretion is caused by an increased vagal tone secondary to VMN
lesions in humans (Lustig et al., 2003; Ahmet et al., 2006)a si n
rats (Bray and Nishizawa, 1978), it is unclear how the increased
vagal tone and decreased sympathetic tone affect secretion of dif-
ferentgutpeptides.Ithasbeenshownthattheanorexigeniceffects
of peripheral administration of both PYY on FI and activation
of ARC neurons are abolished following either bilateral sub-
diaphragmatictotaltruncalvagotomyorbrainstem-hypothalamic
pathway transectioning in rodents (Abbott et al., 2005). In addi-
tion, it has been reported that disturbed adrenergic sympathetic
dysregulation in obesity inﬂuences anorexigenic gut hormone
secretion,in particular PYY release (Lin et al.,2003). Even though
vagotomy is currently a therapeutic approach for treating hypo-
thalamic obesity (HO) in CP patients (Lustig et al., 2009), from
a mechanistic standpoint it remains unclear if potential beneﬁts,
e.g.,reduction of hyperinsulinemia,outweigh potential problems,
e.g., disturbed post-meal gut hormone release. Long acting GLP-
1 agonists, and orally active inhibitors of the incretin-degrading
enzyme dipeptidyl peptidase-IV are approved for treating type-2
diabetes (Bailey,2005; DeFronzo et al.,2005),and it is compelling
to test in future studies the responsiveness to peripherally injected
gut peptides in HO,as these might offer human obesity treatment
opportunities.
HYPOTHALAMIC OBESITY: WHAT CAN BE LEARNED FROM
ELECTROLYTIC AND CHEMICAL LESION MODELS IN RODENTS?
Patients with CP often complain about uncontrolled hunger. As
early as, Brobeck et al. (1943) described rats with lesions in the
VMN as “voracious,” whereas lesions of the LHA led to anorexia
and cachexia. Electrolytic or surgical lesions in the PVN pro-
duced extreme overeating and obesity, suggesting an important
role for this nucleus in energy regulation. However, conﬂicting
results have been published. PVN lesions lead to marked stimu-
lation of FI, but variable frequencies of obesity (Tokunaga et al.,
1991, 1993). VMN-lesioned rats showed lower activity levels and
disturbed circadian rhythms, whereas rats with PVN lesions did
not (Tokunaga et al., 1991). Rats treated at neonatal age with
monosodium l-glutamate (MSG) develop neuroendocrine and
metabolic abnormalities, resulting in a phenotype of adiposity
characterized by GH deﬁciency (Kubota et al., 1994), hyperinsu-
linemia (de Souza et al.,2003),and hyperleptinemia,due to leptin
resistance (Perello et al., 2004). Vagotomy decreased high insulin
secretioninducedinMSG-obeserats(Balboetal.,2002).Neonatal
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administration of MSG to rodents and monkeys destroyed 80–
90% of the ARC, showing cell rariﬁcation and cell death most
signiﬁcantly in the rostromedial ARC, but also in the adjacent
VMNwherecelldensitywasnotdistinctlyreduced(Schoelchetal.,
2002), resulting in several neuroendocrine and metabolic abnor-
malities and decreased thermogenesis. In hamster studies, MSG
decreased numbers of hypothalamic neuropeptide-Y (NPY)- and
agouti-relatedpeptide(AgRP)ﬁbersinthePVN,becausetheARC
has projections to the PVN, including α-MSH projections (Leit-
ner and Bartness,2008). MSG-treated animals develop an obesity
syndrome in the absence of hyperphagia (Dawson et al., 1989;
Elfers et al., 2011; Roth et al., 2011b), characterized by excess fat
deposition and reduced lean body mass,accompanied by reduced
metabolicrates,duetodecreasedsympatheticactivationof brown
adipose tissue (Poon and Cameron,1978). Recently we developed
a rat model of combined medial hypothalamic lesion (CMHL)
affecting the VMN, DMN, and the ARC. Only the CMHL model
exhibitedallkeyfeaturesobservedinpatientswithHOinducedby
CP (Elfers et al.,2011; Roth et al.,2011b). These features included
excessive weight gain due to increased adiposity, increased FI,
and pronounced hyperinsulinemia and hyperleptinemia. Simi-
lar to ﬁndings in CP patients (Roth et al., 2010), CMHL animals
exhibited reduced plasma levels of alpha-melanocyte stimulating
hormone and reduced ambulatory activity compared to weight-
matched controls. Ablation of the ARC/VMN can destroy the
leptin sensitive melanocortin ARC–PVN circuit affecting satiety
signaling not only in the hypothalamus but also in the hindbrain
(seemodelFigure2). The CMHL model best mimics the complex
metabolic abnormalities observed in obese CP patients compared
to lesions to other hypothalamic areas and provides a foundation
for future pharmacological approaches to treat obesity in children
with hypothalamic damage.
HYPOTHALAMIC OBESITY: RESULTS FROM STUDIES IN
HUMANS
IMAGING STUDIES AND FOOD REWARD
Risk factors for developing obesity in CP patients include: large
hypothalamic lesions and tumors that reach the ﬂoor of the third
ventricle; hydrocephalus; aggressive resection; and hypothalamic
irradiation(Mulleretal.,2007;Gardneretal.,2008;Vinchonetal.,
2009). Extensive hypothalamic inﬁltration and a completely deﬁ-
cient third ventricle have been associated with the highest risk of
obesity (DeVile et al., 1996; Pascual et al., 2008). however, results
arenotentirelyconsistent(Daousietal.,2005).Disturbanceof the
hypothalamus by the tumor itself (Vinchon et al.,2009) and/or its
radiation/surgical treatment has been discussed as a major cause
of hyperphagia and obesity. In our own clinical series we found
in patients with morbid obesity lesions affecting several medial
hypothalamic nuclei such as ARC, VMN, and DMN (representa-
tive picture is shown in Figure1). Functional magnetic resonance
imaging(fMRI)isapowerfultoolforobservingthehumanbrain’s
in vivo responses to stimuli. The question is whether damage to
homeostatic centers, such as medial hypothalamic nuclei by CP,
also alters eating behavior by alteration of neuronal activity in
food reward brain areas (see for schematic overview Figure 2)
and whether central processing of satiety is affected. In a pilot
FIGURE2|K e yr egulators of energy homeostasis in the brain. Model
of weight regulatory circuits and hypothalamic nuclei potentially affected
by craniopharyngioma and surgery (gray area).The lesion of medial
hypothalamic nuclei (ARC, VMN, DMN) typically does not involve the
lateral hypothalamus (LHA) potentially leading to unbalanced expression
and secretion of orexigens (MCH, orexigens A and B) by the LHA.
Additionally the communication to (1) higher cortical brain areas and limbic
system involved in food reward and eating behavior, (2) pituitary, and (3)
hindbrain nuclei (AP , area postrema, NTS: solitary tract nucleus) affecting
the autonomous nervous control of effectors in pancreas, liver, adipose
tissue, GI tract, muscle, CV system might be affected as well. CRF ,
corticotrophin relasing factor;TRH, thyrotropin-releasing hormone; NPY,
neuropeptide-Y; GABA, gamma aminobutyric acid; BDNF , brain-derived
neurotrophic factor; POMC, proopiomelanocortin; AgRP , agouti-related
peptide; CART, cocaine amphetamine regulated transcript; α-MSH,
alpha-melanocyte stimulating hormone.
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study, we utilized fMRI to examine food-related activity in brain
centers that control appetite. We hypothesized that hypothalamic
damage due to CP and its treatment results in enhanced percep-
tion of food reward. Participants viewed blocked photographs of
food and mean z-scores for regions of interest (ROI; bilateral N.
accumbens,insula,striatum,andmedialorbitofrontalcortex)were
calculatedforthecontrastof fattening>non-fatteningfood.Sub-
jects underwent the ﬁrst fMRI scan, received a high-calorie test
meal to suppress appetite, and had a second fMRI scan 30min
after the test meal. Before and after the scans,hunger ratings were
performed. Following the test meal, controls showed suppression
of activation in ROIs while CP patients showed trends toward
higher activation in ROIs (Roth et al., 2011a). These preliminary
data support our hypothesis that perception of food cues may be
altered in HO, especially after eating. The fMRI approach may be
applicableforperformingfuturemechanisticstudiesof thebrains’
response to food in patients with HO.
CENTRAL AND PERIPHERAL PEPTIDES INVOLVED IN ENERGY
HOMEOSTASIS
There is good evidence for alterations in peripheral hormone sig-
naling in CP. Previous clinical studies showed that hypothalamic
tumor involvement leads to greater leptin resistance in patients
with CP than in obese controls (Roth et al.,1998). CP patients are
reported to be less physically active than controls with compara-
ble BMIs (Harz et al., 2003) and catecholamine levels are lower in
CP patients, indicating low sympathetic tone (Roth et al., 2007).
Plasma α-MSH levels were signiﬁcantly reduced in CP, similar to
ﬁndingsinourCMHLratmodel,whichmightexplainlowerEEin
peripheral tissues via reduced fat and muscle fatty acid oxidation
(Rothetal.,2010).InanancillarystudytotheGermanmulticenter
study Kraniopharyngeom 2000,plasma insulin,and gut hormone
responses,such as ghrelin and PYY,in response to meal tests were
assessedinleanandobeseCPpatientsandBMImatchedcontrols.
ObeseCPsubjectshadsigniﬁcantlyhigherbaselineandpost-meal
insulin and weaker post-meal changes for PYY compared to obese
controls. Patients with hypothalamic CP had signiﬁcantly weaker
post-meal reduction of ghrelin levels than CP without hypothala-
mic localization (Roth et al., 2011c). In sum, prior studies of HO
have shown impaired function of peripherally released hormones
that act centrally to modulate responses to food (see Figure 3).
SUMMARY AND ETIOLOGICAL THEORIES
Damage of medial hypothalamic nuclei due to the tumor and
its treatment is frequently seen in patients with CP leading to
HO characterized by fatigue, decreased physical activity, uncon-
trolledappetite,andmorbidobesity,andisassociatedwithinsulin
and leptin resistance. Disruption of feeding circuits by damage of
medial hypothalamic nuclei has the potential to increase hunger,
by (i) enhancing the response to orexigenic signals such as ghrelin
andbystimulatingtheorexigenicsignalingthroughNPY/AgRPor
(ii) blocking the response to adiposity signals such as leptin and
inhibiting the anorexigenic POMC signaling in the hypothalamus
(Figure2). Ineithercase,theresultcaninvolveunopposedactiva-
tion of the LHA which increases FI while decreasing sympathetic
nervous system (SNS)-mediated stimulation of EE.VMN damage
can lead to disinhibition of the vagal tone, resulting in excess
FIGURE 3 | Hypothetical model of disturbed energy homeostasis in
hypothalamic obesity.
FIGURE 4 | Summary of metabolic and clinical ﬁndings involved in
dysregulated energy balance in hypothalamic obesity.
stimulation of pancreatic β-cells, hyperinsulinemia, and obesity
(Lustig et al., 2003). Alternatively, the sympathetic nervous out-
put might be reduced,leading to decreased physical activity (Harz
et al., 2003; Roth et al., 2007). As the hypothalamic damage in
CP frequently includes the ARC, which is the main hypothalamic
binding site for hormones from the periphery (Figures 2 and 3),
thehypothalamusmightbeunabletorespondnormallytoadipos-
ity and satiety signals such as insulin, leptin, and gut hormones,
including PYY and ghrelin (Stellar, 1954; Blundell, 1982, 1990;
Inge et al., 2007). In addition, excessive weight gain could be the
result of deﬁcient hypothalamic neural circuits communicating
with corticolimbic and other brain regions to regulate appetite
and thus leading to unbalanced eating (see summary Figure 4).
ACKNOWLEDGMENTS
The author thanks Michael W. Schwartz, and Gregory Morton,
DiabetesandObesityCenterof Excellence,Seattle,aswellasJames
Blevins, Department of Veterans Affairs Medical Center, Seattle,
WA,USA,for their constructive ideas and comments while devel-
oping the CMHL rat model. In addition the author is grateful to
Ellen Schur, Department of Medicine, University of Washington,
for her support in functional neuroimaging studies, as well as to
Clinton Elfers, for his expertise in performing rat studies.
Frontiers in Endocrinology | Pituitary Endocrinology October 2011 | Volume 2 | Article 49 | 4Roth Mechanisms of hypothalamic obesity
REFERENCES
Abbott, C. R., Monteiro, M., Small, C.
J.,Sajedi,A.,Smith,K. L.,Parkinson,
J. R., Ghatei, M. A., and Bloom, S.
R. (2005). The inhibitory effects
of peripheral administration of
peptide YY(3-36) and glucagon-
like peptide-1 on food intake
are attenuated by ablation of the
vagal-brainstem-hypothalamic
pathway. Brain Res. 1044,
127–131.
Ahmet, A., Blaser, S., Stephens, D.,
Guger, S., Rutkas, J. T., and Hamil-
ton, J. (2006). Weight gain in
craniopharyngioma–am o d e lf o r
hypothalamic obesity. J. Pediatr.
Endocrinol. Metab. 19, 121–127.
Bai, F. L., Yamano, M., Shiotani,
Y., Emson, P. C., Smith, A. D.,





Brain Res. 331, 172–175.
Bailey, C. J. (2005). Drugs on the hori-
zon for diabesity. C u r r .D i a b .R e p .5,
353–359.
Balbo, S. L., Bonﬂeur, M. L., Carneiro,
E. M., Amaral, M. E., Filiputti, E.,
and Mathias, P. C. (2002). Parasym-
pathetic activity changes insulin
response to glucose and neurotrans-
mitters. Diabetes Metab. 28, 3S13–
3S17; discussion 3S108–3S112.
Batterham, R. L., Cowley, M. A., Small,
C. J., Herzog, H., Cohen, M. A.,
Dakin, C. L., Wren, A. M., Brynes,
A. E., Low, M. J., Ghatei, M. A.,
Cone,R.D.,andBloom,S.R.(2002).
Gut hormone PYY(3-36) physiolog-
ically inhibits food intake. Nature
418, 650–654.
Berthoud, H. R., and Morrison, C.
(2008).Thebrain,appetite,andobe-
sity. A n n u .R e v .P s y c h o l .59, 55–92.
Bi,S.(2007).Roleof dorsomedialhypo-
thalamic neuropeptide Y in energy
homeostasis. Peptides 28, 352–356.
Blevins, J. E., Morton, G. J., Williams,
D. L., Caldwell, D. W., Bastian, L.
S., Wisse, B. E., Schwartz, M. W.,
and Baskin, D. G. (2009). Forebrain
melanocortinsignalingenhancesthe
hindbrain satiety response to CCK-
8.Am.J.Physiol.Regul.Integr.Comp.
Physiol. 296, R476–R484.
Blundell, J. E. (1982). Neuroregula-
tors and feeding: implications for
the pharmacological manipulation
of hunger and appetite. Rev. Pure
Appl. Pharmacol. Sci. 3, 381–462.
Blundell, J. E. (1990). Appetite distur-
bance and the problems of over-
weight. Drugs 39(Suppl. 3), 1–19.
Brauner, R., Malandry, F., Rappaport,
R., Pierre-Kahn, A., and Hirsch, J.
F. (1987). Craniopharyngioma in
children. Endocrine evaluation and
treatment.Aproposof37cases.Arch.
Fr. Pediatr. 44, 765–769.
Bray, G. A., and Nishizawa, Y. (1978).
Ventromedial hypothalamus modu-
lates fat mobilisation during fasting.
Nature 274, 900–902.
Brobeck, J. R., Tepperman, J., and
Long, C. N. H. (1943). Experimen-
tal hypothalamic hyperphagia in the
albino rat. Yale J. Biol. Med. 15,
831–853.
Choi, S., Sparks, R., Clay, M., and Dall-
man, M. F. (1999). Rats with hypo-
thalamic obesity are insensitive to
centralleptininjections.Endocrinol-
ogy 140, 4426–4433.
Cota, D., Proulx, K., Smith, K. A.,
Kozma, S. C., Thomas, G., Woods,
S. C.,and Seeley,R. J. (2006). Hypo-
thalamic mTOR signaling regulates
food intake. Science 312, 927–930.
Curtis, J., Daneman, D., Hoffman,
H. J., and Ehrlich, R. M. (1994).
The endocrine outcome after surgi-
cal removal of craniopharyngiomas.
Pediatr. Neurosurg. 21(Suppl. 1),
24–27.
Daousi, C., Dunn, A. J., Foy, P. M.,
MacFarlane, I. A., and Pinkney,
J. H. (2005). Endocrine and neu-
roanatomic features associated with
weight gain and obesity in adult
patientswithhypothalamicdamage.
A m .J .M e d .118, 45–50.
Dawson, R. Jr., Wallace, D. R., and
Gabriel, S. M. (1989). A pharma-
cological analysis of food intake
regulation in rats treated neona-
tally with monosodium L-glutamate
(MSG). Pharmacol. Biochem. Behav.
32, 391–398.
de Souza, C. T., Nunes,W. M., Gobatto,
C. A., and de Mello, M. A. (2003).
Insulin secretion in monosodium
glutamate (MSG) obese rats sub-
mitted to aerobic exercise training.
Physiol. Chem. Phys. Med. NMR 35,
43–53.
DeFronzo, R. A., Ratner, R. E., Han,
J., Kim, D. D., Fineman, M. S.,
and Baron, A. D. (2005). Effects of
exenatide (exendin-4) on glycemic
control and weight over 30 weeks
in metformin-treated patients with




K. E., and Hayward, R. D. (1996).
Management of childhood cranio-
pharyngioma: can the morbidity of
radical surgery be predicted? J. Neu-
rosurg. 85, 73–81.
Elfers, C., Ralston, M., and Roth, C. L.
(2011). Studies of different female
rat models of hypothalamic obesity.
J. Pediatr. Endocrinol. Metab. 24,
131–137.
Figlewicz, D. P. (2003). Insulin, food
intake, and reward. Semin. Clin.
Neuropsychiatry 8, 82–93.
Figlewicz,D.P.,andBenoit,S.C.(2009).
Insulin, leptin, and food reward:
update 2008. Am. J. Physiol. Regul.
Integr. Comp. Physiol. 296, R9–R19.
Figlewicz, D. P., MacDonald Naleid, A.,
and Sipols,A. J. (2007). Modulation
of food reward by adiposity signals.
Physiol. Behav. 91, 473–478.
Galatzer, A., Nofar, E., Beit-Halachmi,
N., Aran, O., Shalit, M., Roitman,
A.,andLaron,Z.(1981).Intellectual
and psychosocial functions of chil-
dren, adolescents and young adults
before and after operation for cran-
iopharyngioma. Child Care Health
Dev. 7, 307–316.
Gardner, P. A., Kassam, A. B., Snyder-
man, C. H., Carrau, R. L., Mintz,
A. H., Grahovac, S., and Stefko, S.
(2008). Outcomes following endo-
scopic, expanded endonasal resec-
tion of suprasellar craniopharyn-
giomas: a case series. J. Neurosurg.
109, 6–16.
Glavas, M. M., Joachim, S. E., Draper,
S. J., Smith, M. S., and Grove, K.
L. (2007). Melanocortinergic activa-
tionbymelanotanIIinhibitsfeeding
and increases uncoupling protein 1
messenger ribonucleic acid in the
developing rat. Endocrinology 148,
3279–3287.
Harz, K. J., Muller, H. L., Waldeck, E.,
Pudel,V., and Roth, C. (2003). Obe-
sity in patients with craniopharyn-
gioma: assessment of food intake
and movement counts indicating
physical activity. J. Clin. Endocrinol.
Metab. 88, 5227–5231.
Imura,H.,Kato,Y.,andNakai,Y.(1987).
Endocrine aspects of tumors aris-
ing from suprasellar, third ventric-
ular regions. Prog. Exp. Tumor Res.
30, 313–324.
Inge, T. H., Pﬂuger, P., Zeller, M.,
Rose, S. R., Burget, L., Sundarara-
jan, S., Daniels, S. R., and Tschop,
M.H.(2007).Gastricbypasssurgery
for treatment of hypothalamic obe-
sity after craniopharyngioma ther-
apy. Nat. Clin. Pract. Endocrinol.
Metab. 3, 606–609.
Kerkerian, L., and Pelletier, G. (1986).
Effects of monosodium L-glutamate
administration on neuropeptide Y-
containing neurons in the rat hypo-
thalamus. Brain Res. 369, 388–390.
Kubota, A., Nakagawa, Y., and Igarashi,
Y. (1994). Studies of gene expression
in liver of insulin-like growth factor
(IGF)-I, IGF binding protein-
3 and growth hormone (GH)
receptor/GH binding protein
in rats treated neonatally with
monosodium glutamate. Horm.
Metab. Res. 26, 497–503.
Leitner, C., and Bartness, T. J. (2008).
Food deprivation-induced changes
in body fat mobilization after
neonatal monosodium gluta-
mate treatment. Am. J. Physiol.
Regul. Integr. Comp. Physiol. 294,
R775–R783.
Lin, H. C., Neevel, C., Chen, P. S., Suh,
G., and Chen, J. H. (2003). Slowing
of intestinal transit by fat or pep-
tide YY depends on beta-adrenergic
pathway.Am. J. Physiol. Gastrointest.
Liver Physiol. 285, G1310–G1316.
Lustig, R. H., Post, S. R., Srivanna-
boon, K., Rose, S. R., Danish, R.
K., Burghen, G. A., Xiong, X., Wu,
S., and Merchant, T. E. (2003).
Risk factors for the development of
obesity in children surviving brain
tumors. J. Clin. Endocrinol. Metab.
88, 611–616.
Lustig, R. H., Tsai, P., Hirose, S., and
Farmer, D. L. (2009). “Treatment
of hypothalamic obesity by laparo-
scopictruncalvagatomy:earlyexpe-
rience,”inAbstract LWPES/ESPE 8th
Joint Meeting Paediatric Endocrinol-
ogy, Hormone Research 2009, New
York, 72, S3:48.
Morton,G. J.,Cummings,D. E.,Baskin,
D. G., Barsh, G. S., and Schwartz,
M. W. (2006). Central nervous sys-
tem control of food intake and body
weight. Nature 443, 289–295.
Muller,H.L.(2006).Moreorless?Treat-
mentstrategiesinchildhoodcranio-
pharyngioma. Childs Nerv. Syst. 22,
156–157.
Muller, H. L. (2008). Childhood cran-
iopharyngioma. Recent advances in
diagnosis, treatment and follow-up.
Horm. Res. 69, 193–202.
Muller,H.L.,Bueb,K.,Bartels,U.,Roth,
C.,Harz,K.,Graf,N.,Korinthenberg,
R., Bettendorf, M., Kuhl, J., Gut-
jahr, P., Sorensen, N., and Calami-
nus, G. (2001). Obesity after child-
hoodcraniopharyngioma–German
multicenter study on pre-operative
risk factors and quality of life. Clin.
Padiatr. 213, 244–249.
Muller, H. L., Emser, A., Faldum, A.,
Bruhnken, G., Etavard-Gorris, N.,
Gebhardt, U., Oeverink, R., Kolb,
R., and Sorensen, N. (2004). Longi-
tudinal study on growth and body
mass index before and after diag-
nosis of childhood craniopharyn-
gioma.J.Clin.Endocrinol.Metab.89,
3298–3305.
Muller, H. L., Gebhardt, U., Wessel, V.,
Schroder, S., Kolb, R., Sorensen, N.,
Maroske, J., and Hanisch, E. (2007).
First experiences with laparoscopic
adjustable gastric banding (LAGB)
in the treatment of patients with
childhood craniopharyngioma and
morbid obesity. Klin. Padiatr. 219,
323–325.
www.frontiersin.org October 2011 | Volume 2 | Article 49 | 5Roth Mechanisms of hypothalamic obesity
Parton, L. E., Ye, C. P., Coppari, R.,
Enriori, P. J., Choi, B., Zhang, C.
Y., Xu, C., Vianna, C. R., Balthasar,
N., Lee, C. E., Elmquist, J. K., Cow-
ley, M. A., and Lowell, B. B. (2007).
Glucose sensing by POMC neurons
regulates glucose homeostasis and
is impaired in obesity. Nature 449,
228–232.
Pascual, J. M., Carrasco, R., Prieto,
R., Gonzalez-Llanos, F., Alvarez, F.,
and Roda, J. M. (2008). Cranio-
pharyngioma classiﬁcation. J. Neu-
rosurg. 109,1180–1182;author reply
1182–1183.
Perello, M., Moreno, G., Gaillard,
R. C., and Spinedi, E. (2004).
Glucocorticoid-dependency of
increased adiposity in a model
of hypothalamic obesity. Neuro
Endocrinol. Lett. 25, 119–126.
Petrovich, G. D., Setlow, B., Holland,
P. C., and Gallagher, M. (2002).
Amygdalo-hypothalamic circuit
allows learned cues to override sati-
ety and promote eating. J. Neurosci.
22, 8748–8753.
Poon, T. K., and Cameron, D. P.
(1978). Measurement of oxygen
consumption and locomotor activ-
ity in monosodium glutamate-
induced obesity. Am. J. Physiol. 234,
E532–E534.
Roth, C. L., Aylward, E., Liang,
O., Pauley, G., Kleinhans, N. M.,
and Schur, E. (2011a). Func-
tional neuroimaging in cranio-
pharyngioma: useful tool to bet-
ter understand hypothalamic obe-
sity? Abstract Annual Meeting The
Endocrine Society, Boston.
Roth, C. L., Blevins, J. E., Ralston, M.,
Elfers, C., Ogimoto, K., Kaiyala, K.
J., and Morton, G. J. (2011b). A
novel rodent model that mimics the
metabolic sequelae of obese cranio-
pharyngioma patients. Pediatr. Res.
69, 230–236.
Roth, C. L., Gebhardt, U., and Muller,
H. L. (2011c). Appetite-regulating
hormone changes in patients with
craniopharyngioma. Obesity (Silver
Spring) 19, 36–42.
Roth, C. L., Enriori, P. J., Gebhardt,
U., Hinney, A., Muller, H. L., Hebe-
brand, J., Reinehr, T., and Cowley,
M. A. (2010). Changes of peripheral
alpha-melanocyte-stimulating hor-
mone in childhood obesity. Metab.
Clin. Exp. 59, 186–194.
Roth, C. L., Hunneman, D. H.,
Gebhardt, U., Stoffel-Wagner, B.,
Reinehr,T.,andMuller,H.L.(2007).
Reduced sympathetic metabolites in
urine of obese patients with cran-
iopharyngioma. Pediatr. Res. 61,
496–501.
Roth, C. L., Wilken, B., Hanefeld, F.,
Schroter, W., and Leonhardt, U.
(1998). Hyperphagia in children
with craniopharyngioma is associ-
ated with hyperleptinaemia and a
failure in the downregulation of
appetite. Eur. J. Endocrinol. 138,
89–91.
Sahu, A., Kalra, S. P., Crowley, W.
R., and Kalra, P. S. (1988). Evi-
dence that NPY-containing neurons
inthebrainstemprojectintoselected
hypothalamic nuclei: implication in
feeding behavior. Brain Res. 457,
376–378.
Sawchenko, P. E., Swanson, L. W.,
Grzanna, R., Howe, P. R., Bloom,
S. R., and Polak, J. M. (1985).
Colocalization of neuropeptide Y
immunoreactivity in brainstem cat-
echolaminergicneuronsthatproject
to the paraventricular nucleus of the
hypothalamus.J.Comp.Neurol.241,
138–153.
Schoelch, C., Hubschle, T., Schmidt,
I., and Nuesslein-Hildesheim, B.
(2002). MSG lesions decrease
body mass of suckling-age rats by
attenuating circadian decreases of
energy expenditure. Am. J. Physiol.
Endocrinol. Metab. 283, E604–E611.
Schwartz, M. W. (2006). Central
nervous system regulation of food
intake. Obesity (Silver Spring)
14(Suppl. 1), 1S–8S.
Schwartz, M. W., and Gelling, R. W.
(2002). Rats lighten up with MCH
antagonist. Nat. Med. 8, 779–781.
Schwartz, M. W., Woods, S. C., Porte,
D. Jr., Seeley, R. J., and Baskin, D.
G. (2000). Central nervous system
control of food intake. Nature 404,
661–671.
Small,C.J.,Parkinson,J.R.,andBloom,
S. R. (2005). Novel therapeutic tar-
gets for appetite regulation. Curr.
Opin. Investig. Drugs 6, 369–372.
Sorva, R. (1988). Children with cran-
iopharyngioma. Early growth fail-
ure and rapid postoperative weight
gain. Acta Paediatr. Scand. 77,
587–592.
Stellar, E. (1954). The physiology of
motivation. Psychol. Rev. 61, 5–22.
Tokunaga, K., Bray, G. A., and Mat-
suzawa,Y. (1993). Improved yield of
obese rats using a double coordinate
system to locate the ventromedial or
paraventricular nucleus. Brain Res.
Bull. 32, 191–194.
Tokunaga, K., Matsuzawa, Y., Fujioka,
S., Kobatake, T., Keno, Y., Odaka,
H., Matsuo, T., and Tarui, S. (1991).
PVN-lesioned obese rats maintain
ambulatory activity and its circa-
dian rhythm. Brain Res. Bull. 26,
393–396.
Vinchon, M., Weill, J., Delestret, I.,




Wynne, K., Stanley, S., McGowan, B.,
and Bloom, S. (2005). Appetite con-
trol. J. Endocrinol. 184, 291–318.
Conﬂict of Interest Statement: The
author declares that the research was
conducted in the absence of any
commercial or ﬁnancial relationships
that could be construed as a potential
conﬂict of interest.
Received: 25 August 2011; paper pending
published: 15 September 2011; accepted:
19 September 2011; published online: 14
October 2011.
Citation: Roth CL (2011) Hypo-
thalamic obesity in patients with
craniopharyngioma: profound changes
of several weight regulatory cir-
cuits. Front. Endocrin. 2:49. doi:
10.3389/fendo.2011.00049
This article was submitted to Frontiers
in Pituitary Endocrinology, a specialty of
Frontiers in Endocrinology.
Copyright © 2011 Roth. This is an open-
access article subject to a non-exclusive
license between the authors and Frontiers
Media SA, which permits use, distribu-
tion and reproduction in other forums,
provided the original authors and source
are credited and other Frontiers condi-
tions are complied with.
Frontiers in Endocrinology | Pituitary Endocrinology October 2011 | Volume 2 | Article 49 | 6